Japan’s Ministry of Health, Labor and Welfare approved LivaNova’s sutureless aortic heart valve for treating aortic valve disease.

The device, known as the Perceval sutureless valve, is designed to lessen the physiological impact of aortic valve replacement. It received the FDA’s approval in 2016.

The valve can be used in a variety of surgical methods, including traditional procedures and minimally invasive approaches.